Drugs / autologous dendritic cell vaccine
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01241162 | Aug 2010 → Oct 2016 | Ewing sarcoma, neuroblastoma, osteosarcoma, rhabdomyosarcoma +1 | University of Louisville | Completed | No outcome recorded |
| Phase 1 | NCT00834002 | Mar 2005 → Nov 2007 | acute myeloid leukemia | University Hospital, Antwerp | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT01883518 | Jun 2013 → Sep 2020 | soft tissue sarcoma | N.N. Petrov National Medical Research Center of Oncology | Unknown | No outcome recorded |
| Phase 1/2 | NCT00243529 | Apr 2004 → Feb 2009 | melanoma | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT02718391 | Aug 2015 → Nov 2019 | melanoma | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Terminated | No outcome recorded |
| Phase 2 | NCT01973322 | Oct 2013 → Sep 2023 | cutaneous melanoma | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Completed | No outcome recorded |
| Phase 2 | NCT00099593 | Sep 2004 → Sep 2007 | Sezary syndrome, primary cutaneous T-cell lymphoma | University of Pittsburgh | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT01530698 Comparator | Apr 2010 → Nov 2014 | melanoma | Radboud University Medical Center | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | autologous dendritic cell vaccine | “intradermal injection of WT1-RNA-electroporated autologous dendritic cell vaccine (therapeutic cell vaccine)” NCT00834002 ↗7“Intradermal Autologous Dendritic Cell Vaccine loaded with autologous tumor lysate or homogenate” NCT01973322 ↗ |
| Action | Deplete | “may induce an effective immune response to kill residual leukemic cells” NCT00834002 ↗ |
| Modality | Vaccine | “DC-tumor cell vaccines have several features” NCT00099593 ↗ |
| Route | Other | “intradermal injection” NCT00834002 ↗ |